NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells - PubMed (original) (raw)
NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells
Yoshiteru Sasaki et al. Proc Natl Acad Sci U S A. 2008.
Abstract
BAFF-R-dependent activation of the alternative NF-kappaB pathway plays an essential role in mature B cell survival. Mutations leading to overexpression of NIK and deletion of the TRAF3 gene are implicated in human multiple myeloma. We show that overexpression of NIK in mouse B lymphocytes amplifies alternative NF-kappaB activation and peripheral B cell numbers in a BAFF-R-dependent manner, whereas uncoupling NIK from TRAF3-mediated control causes maximal p100 processing and dramatic hyperplasia of BAFF-R-independent B cells. NIK controls alternative NF-kappaB signaling by increasing the protein levels of its negative regulator TRAF3 in a dose-dependent fashion. This mechanism keeps NIK protein levels below detection even when they cause B cell hyperplasia, so that contributions of NIK to B cell pathologies can easily be overlooked.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Fig. 1.
NIKΔT3 expression strongly induces the alternative NF-κB pathway. (A) NIK or NIKΔT3 are expressed under control of the ROSA26 promoter after Cre-mediated deletion of the loxP-flanked STOP cassette. Flag-tagged wild-type NIK and NIKΔT3, which lacks the T3BD (amino acids 78–84) were used for this approach. KD, kinase domain. (B) B cell-specific expression of the IRES-eGFP-containing construct can be verified by FACS analysis. (C–H) Western blot analysis of extracts from control, NIKtg, and NIKΔT3tg B cells, as indicated above the individual blots. The levels of β-actin, tubulin, and lamin B1 are shown as loading controls for whole-cell, cytoplasmic (C), and nuclear (N) extracts, respectively. Numbers in red indicate average quantifications (normalized to the respective loading controls) relative to controls of four (D), five (E), three to six (F), four (G), or three to four (H) experiments.
Fig. 2.
B cell hyperplasia induced by NIK or NIKΔT3 expression. (A) Macroscopic appearance of spleen and lymph nodes. Bold red numbers below the spleens or lymph nodes indicate the average number of B cells (× 106) in three age-matched mice, respectively. (B) FACS analysis shows the proportions of transitional B220+AA4.1+ and mature B220+AA4.1− B cells in the spleens of control, B cellNIK, and B cellNIKΔT3 mice. Numbers next to individual gates refer to the percentages of transitional and mature splenic B cells of total lymphocytes. (C) Immunohistochemical analyses of spleen sections with anti-B220 (blue) and anti-MOMA1 (red) shows the ring of metallophilic macrophages (red) encircling the B cell (blue) follicles (FO). Blue staining outside the follicles represents MZ B cells. (Magnification: Upper, ×40; Lower, ×200.) (D) Hematoxylin/eosin staining of Peyer's patch and nasal-associated lymphoid tissue (NALT) sections from a B cellNIKΔT3 mouse. (E) FACS analysis of cell-surface marker expression on NIKΔT3tg and CD19-cre control B cells. Results are representative of at least three independent experiments. (F) Susceptibility of ex vivo isolated cells of the indicated genotypes to Fas-induced apoptosis. The percentages of life Fas-treated cells of life control antibody-treated cells are shown as mean and standard deviation of three independent experiments. (G) DNA-content analysis of ex vivo isolated control, NIKtg, and NIKΔT3tg B cells. The percentages of cells in different phases of the cell cycle (G0/G1, G2/M, and S) are indicated in red; one representative plot of three independent experiments is shown.
Fig. 3.
Uncoupling of NIK from TRAF3-mediated negative regulation renders B cells independent of BAFF-R signaling. (A) FACS analysis of splenic B cell populations. Bold red numbers indicate the average number of mature B220+AA4.1− splenic B cells (× 106) (n = 2–4). The numbers next to individual gates refer to the percentages of transitional B220+AA4.1+ and mature splenic B cells (Upper) or of mature follicular IgMlowIgDhigh B cells (Lower) of total lymphocytes. (B) Immunohistochemical analysis of spleen sections. Anti-B220 (blue) stains follicular B cells inside the ring of MOMA1+ (red) metallophilic macrophages. (Magnification: ×200.) (C) Cytoplasmic (C) and nuclear (N) levels of PKCδ, p100/p52, RelB, IκBα, p105/p50, and RelA analyzed by Western blotting in extracts prepared from B cells cultured in medium with or without 500 ng of BAFF/ml for 24 h. Tubulin and lamin B1 levels demonstrate purity and equal loading of cytosolic and nuclear fractions, respectively. This experiment was repeated once with identical results.
Fig. 4.
NIK protein level and activity are controlled by a negative feedback loop involving TRAF2/3. (A) Western blot analysis of TRAF2 and TRAF3 protein levels in purified splenic B cells of the indicated genotypes. (B) Western blot analysis of cytoplasmic (C) and nuclear (N) protein amounts of NIK, p100/p52, RelB, TRAF2, and TRAF3 in splenic B cells. (C) Northern blot analysis of Traf2, Traf3, and _IκB_α mRNA levels in CD43-depleted splenic B cells. Numbers in red indicate average quantifications (normalized to the respective loading controls) relative to controls of three (A), one (B), or two to three (C) experiments.
Fig. 5.
Scheme of BAFF:BAFF-R-induced alternative NF-κB activation via TRAF2, TRAF3, and NIK. During normal B cell physiology (A), BAFF:BAFF-R interactions induce the degradation of TRAF3, which binds to NIK at the T3BD and together with TRAF2 negatively regulates NIK protein levels. NIK activity stimulates B cell survival via the activation of predominantly alternative NF-κB and increases the TRAF2 and, more prominently, TRAF3 protein levels in a negative feedback interaction. (B) In the absence of BAFF:BAFF-R interactions, TRAF3 accumulates and together with TRAF2 induces the complete degradation of NIK, leading to shutdown of alternative NF-κB activity and cellular apoptosis. (C) In the presence of BAFF, increased expression of NIK leads to a steady state of enhanced NF-κB signaling and B cell survival and enhanced levels of TRAF2 and TRAF3, which keep NIK protein level below detection. Absence of BAFF (B) still results in TRAF2/3-mediated degradation of NIK and apoptosis. The activity of increased de novo generated NIK mostly likely slightly increases BAFF-independent survival. (D) NIKΔT3 induces BAFF-independent maximal p100 processing and B cell survival and very high TRAF2 and TRAF3 protein levels, which, however, cannot impact on NIKΔT3 protein levels.
Similar articles
- Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.
Pham LV, Fu L, Tamayo AT, Bueso-Ramos C, Drakos E, Vega F, Medeiros LJ, Ford RJ. Pham LV, et al. Blood. 2011 Jan 6;117(1):200-10. doi: 10.1182/blood-2010-06-290437. Epub 2010 Oct 1. Blood. 2011. PMID: 20889926 Free PMC article. - Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling.
Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H, Vignali DA, Bergsagel PL, Karin M. Vallabhapurapu S, et al. Nat Immunol. 2008 Dec;9(12):1364-70. doi: 10.1038/ni.1678. Epub 2008 Nov 9. Nat Immunol. 2008. PMID: 18997792 Free PMC article. - TACI induces cIAP1-mediated ubiquitination of NIK by TRAF2 and TANK to limit non-canonical NF-kappaB signaling.
Kanno Y, Sakurai D, Hase H, Kojima H, Kobata T. Kanno Y, et al. J Recept Signal Transduct Res. 2010 Apr;30(2):121-32. doi: 10.3109/10799891003634509. J Recept Signal Transduct Res. 2010. PMID: 20184394 - Roles of TRAFs in NF-κB signaling pathways mediated by BAFF.
Tang X, Zhang L, Wei W. Tang X, et al. Immunol Lett. 2018 Apr;196:113-118. doi: 10.1016/j.imlet.2018.01.010. Epub 2018 Feb 20. Immunol Lett. 2018. PMID: 29378215 Review. - Living in context with the survival factor BAFF.
Cancro MP. Cancro MP. Immunity. 2008 Mar;28(3):300-1. doi: 10.1016/j.immuni.2008.02.010. Immunity. 2008. PMID: 18342003 Review.
Cited by
- PUM1-TRAF3 fusion protein activates non-canonical NF-κB signaling via rescued NIK in biliary tract cancer.
Jung DE, Seo MK, Jo JH, Kim K, Kim C, Kang H, Park SB, Lee HS, Kim S, Song SY. Jung DE, et al. NPJ Precis Oncol. 2024 Aug 1;8(1):170. doi: 10.1038/s41698-024-00654-2. NPJ Precis Oncol. 2024. PMID: 39090283 Free PMC article. - Tfl deletion induces extraordinary Cxcl13 secretion and cachexia in VavP-Bcl2 transgenic mice.
Minagawa K, Wakahashi K, Fukui C, Kawano Y, Kawano H, Suzuki T, Ishii S, Sada A, Nishikawa S, Asada N, Katayama Y, Matsui T. Minagawa K, et al. Front Immunol. 2023 May 26;14:1197112. doi: 10.3389/fimmu.2023.1197112. eCollection 2023. Front Immunol. 2023. PMID: 37304286 Free PMC article. - TRAF3-EWSR1 signaling axis acts as a checkpoint on germinal center responses.
Li Y, Zhu L, Ko CJ, Yang JY, Wang H, Manyam G, Wang J, Cheng X, Zhao S, Jie Z. Li Y, et al. J Exp Med. 2023 Aug 7;220(8):e20221483. doi: 10.1084/jem.20221483. Epub 2023 Apr 25. J Exp Med. 2023. PMID: 37097293 Free PMC article. - RelB contributes to the survival, migration and lymphomagenesis of B cells with constitutively active CD40 signaling.
Kuhn LB, Valentin S, Stojanovic K, Strobl DC, Babushku T, Wang Y, Rambold U, Scheffler L, Grath S, John-Robbert D, Blum H, Feuchtinger A, Blutke A, Weih F, Kitamura D, Rad R, Strobl LJ, Zimber-Strobl U. Kuhn LB, et al. Front Immunol. 2022 Aug 30;13:913275. doi: 10.3389/fimmu.2022.913275. eCollection 2022. Front Immunol. 2022. PMID: 36110848 Free PMC article. - The Therapeutic Potential of Targeting NIK in B Cell Malignancies.
Haselager MV, Eldering E. Haselager MV, et al. Front Immunol. 2022 Jul 12;13:930986. doi: 10.3389/fimmu.2022.930986. eCollection 2022. Front Immunol. 2022. PMID: 35911754 Free PMC article. Review.
References
- Courtois G, Gilmore TD. Mutations in the NF-κB signaling pathway: Implications for human disease. Oncogene. 2006;25:6831–6843. - PubMed
- Hayden MS, West AP, Ghosh S. NF-κB and the immune response. Oncogene. 2006;25:6758–6780. - PubMed
- Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: From innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301–310. - PubMed
- Dejardin E. The alternative NF-κB pathway from biochemistry to biology: Pitfalls and promises for future drug development. Biochem Pharmacol. 2006;72:1161–1179. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI057947/AI/NIAID NIH HHS/United States
- R37 AI054636/AI/NIAID NIH HHS/United States
- P01 CA092625/CA/NCI NIH HHS/United States
- AI057947/AI/NIAID NIH HHS/United States
- CA92625/CA/NCI NIH HHS/United States
- AI054636/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous